1. Lanza R, et al. Direct reprogramming of rat neural precursor cells and fibroblasts into pluripotent stem cells.PLoS One. 2010 Mar 24;5(3):e9838.
"In particular, we found that these rat iPS cells could differentiate to midbrain-like dopamine neurons with a high efficiency."
POSSIBLE FUTURE CLINICAL APPLICATION: Parkinson's
2. Lanza R, et al. alpha-Thalassemia-like globin gene expression by primitive erythrocytes derived from human embryonic stem cells. Hemoglobin. 2010 Jan;34(2):145-50.
"unbalanced globin synthesis appears to be an inherent feature of human erythroid cells that synthesize predominantly embryonic-stage globins."
POSSIBLE FUTURE CLINICAL APPLICATION: thalassemia and other erythropoetic disorders.
3. Lanza R, et al. Methods Mol Biol. 2010;636:105-21.
Directed differentiation of red blood cells from human embryonic stem cells."In this chapter, we describe a robust system that can efficiently generate large numbers of hemangioblasts from multiple hESC lines using well-defined conditions and produce functional homogeneous RBCs with oxygen-carrying capacity in large scale."
POSSIBLE CLINICAL APPLICATION: anemias, leukemias
4. Lanza R, et al. Stem Cells. 2010 Apr;28(4):704-12.
Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. "human INDUCED pluripotential stem cells die early."
POSSIBLE CLINICAL APPLICATION: don't used induced stem cells, use human embryonic stem cells themselves.
5. Lanza R, et al. Stem Cells. 2009 Sep;27(9):2126-35.
Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration.
"Here we show long-term functional rescue using hESC-derived RPE in both the RCS rat and Elov14 mouse, which are animal models of retinal degeneration and Stargardt, respectively. hESC-RPE survived subretinal transplantation in RCS rats for prolonged periods (>220 days). The cells sustained visual function and photoreceptor integrity in a dose-dependent fashion without teratoma formation or untoward pathological reactions. Near-normal functional measurements were recorded at >60 days survival in RCS rats. In NIH III immune-deficient mouse model, long-term data (spanning the life of the animals) showed no gross or microscopic evidence of teratoma/tumor formation after subretinal hESC-RPE transplantation. These results suggest that hESCs could serve as a potentially safe and inexhaustible source of RPE for the efficacious treatment of a range of retinal degenerative diseases.
CLINICAL APPLICATION: Stargardt and adult MD. (using hESC derived RPE cells, not induced RPE cells.)
I saw what you were doing....you/coco/ryjo/lucy morgan/you did a good job...same as a grifter in a bar...you come from out of town, case the place out and ask for change for a $20 bill for the phone..'cept you give the b'tender hald a $20 and half a $1 bill...you get $19 back and 4 quarters....move on to the next town and do the other halves...1 $20/bill and 1 $1/bill nets you $19..not the easiest way too nake a $ but same applied here on the genta board...You and your helpers were employed as a smokescreen with all your jibberish. all the while you were not talking about genta stock at all, just trying to make pennies per post by working for the crooks.
The potential is outright tremendous. The price per share outright ridiculous.
Any success in our early human trial will set off something huge. This is not pumping, this is looking at the potential anybody should be able to see.
If you do not see it, fine with me.